Publications in collaboration with researchers from Clínica Universitaria de Navarra (25)

2026

  1. Burden and Impact of Infectious Complications After Allogeneic Hematopoietic Cell Transplantation in Older Patients: A GETH-TC Study

    Transplantation and Cellular Therapy

  2. Correction: Haemostatic changes during CART cell therapy and risk of complications (Cancer Immunology, Immunotherapy, (2026), 75, 4, (130), 10.1007/s00262-026-04371-6)

    Cancer Immunology, Immunotherapy

  3. Demodex-associated dermatoses after allogeneic HSCT: A retrospective multicentre study

    Journal of the European Academy of Dermatology and Venereology

  4. HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study

    eClinicalMedicine, Vol. 91

  5. Haemostatic changes during CART cell therapy and risk of complications

    Cancer Immunology, Immunotherapy, Vol. 75, Núm. 4

  6. Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 32, Núm. 8, pp. 964.e1-964.e15

  7. Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH-TC study

    British Journal of Haematology, Vol. 209, Núm. 1, pp. 197-209

  8. Real-World Validation of the Transplant Conditioning Intensity (TCI) Score in Allogeneic Hematopoietic Cell Transplantation: A Spanish Multicenter Study on behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 32, Núm. 8, pp. 990.e1-990.e8

  9. Timing of Allogeneic Hematopoietic Cell Transplantation after Inotuzumab Ozogamicin Influences Sinusoidal Obstruction Syndrome and Survival in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

    Transplantation and Cellular Therapy

2025

  1. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

    Blood Cancer Journal, Vol. 15, Núm. 1

  2. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study

    Transplant Infectious Disease, Vol. 27, Núm. 5

  3. Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC

    Frontiers in Immunology, Vol. 16

  4. Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC

    Frontiers in Immunology, Vol. 16

  5. Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

    Open Forum Infectious Diseases, Vol. 12, Núm. 11

  6. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care

    Frontiers in Immunology, Vol. 15

  7. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study

    British Journal of Haematology, Vol. 207, Núm. 4, pp. 1504-1516

  8. Progressive Multifocal Leukoencephalopathy (PML) after hematopoietic cell transplantation (HCT): a retrospective study of Infectious Diseases Working Party (IDWP) of the EBMT

    Bone Marrow Transplantation

  9. Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis

    Cancer Immunology, Immunotherapy, Vol. 74, Núm. 6

  10. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation

    Cancers, Vol. 17, Núm. 19

  11. The role of stem cell transplantation in the modern management of multiple myeloma

    Current Opinion in Hematology